Interleukin-17 Receptor A Antagonist [EPC]

2061 reported adverse events

Drugs of this class: BRODALUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-17 Receptor A Antagonist [EPC] class:

# Side effect Count
0 PSORIASIS 504
1 DRUG INEFFECTIVE 240
2 ARTHRALGIA 195
3 INTENTIONAL PRODUCT USE ISSUE 180
4 PSORIATIC ARTHROPATHY 177
5 FATIGUE 174
6 PRODUCT DOSE OMISSION ISSUE 145
7 DISEASE RECURRENCE 139
8 THERAPY INTERRUPTED 139
9 HEADACHE 131
See all common reactions for Interleukin-17 Receptor A Antagonist [EPC]

Drugs of the Interleukin-17 Receptor A Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 VACCINATION SITE DISCHARGE 5 0.7143
1 ANTITHROMBIN III ABNORMAL 1 0.5000
2 ACROKERATOSIS PARANEOPLASTICA 4 0.4444
3 VACCINATION SITE VESICLES 5 0.2273
4 VACCINATION SITE HAEMORRHAGE 5 0.1389
5 COLLAGEN-VASCULAR DISEASE 8 0.1143
6 HEAD AND NECK CANCER METASTATIC 4 0.0952
7 PYODERMA STREPTOCOCCAL 2 0.0800
8 MUCOCUTANEOUS CANDIDIASIS 7 0.0753
9 ENTHESOPHYTE 3 0.0714
See all enriched reactions for Interleukin-17 Receptor A Antagonist [EPC]